Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $698000.0.

  • Utah Medical Products' Non Operating Income fell 1650.72% to $698000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$655000.0, marking a year-over-year decrease of 22107.21%. This contributed to the annual value of -$1000.0 for FY2024, which is 10010.52% down from last year.
  • Utah Medical Products' Non Operating Income amounted to $698000.0 in Q3 2025, which was down 1650.72% from $640000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Non Operating Income ranged from a high of $915000.0 in Q1 2024 and a low of -$2.7 million during Q4 2024
  • In the last 5 years, Utah Medical Products' Non Operating Income had a median value of $680000.0 in 2023 and averaged $224368.4.
  • The largest annual percentage gain for Utah Medical Products' Non Operating Income in the last 5 years was 840000.0% (2023), contrasted with its biggest fall of 35390.52% (2023).
  • Over the past 5 years, Utah Medical Products' Non Operating Income (Quarter) stood at $880000.0 in 2021, then dropped by 11.25% to $781000.0 in 2022, then crashed by 353.91% to -$2.0 million in 2023, then tumbled by 36.06% to -$2.7 million in 2024, then surged by 125.87% to $698000.0 in 2025.
  • Its Non Operating Income stands at $698000.0 for Q3 2025, versus $640000.0 for Q2 2025 and $705000.0 for Q1 2025.